$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 48 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Sell | S | 560.53 | 3,231 | 1,811,072 | 61,285 | 64.5 K to 61.3 K (-5.01 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Sell | S | 559.20 | 500 | 279,600 | 64,516 | 65 K to 64.5 K (-0.77 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Sell | S | 558.43 | 2,118 | 1,182,755 | 65,016 | 67.1 K to 65 K (-3.15 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Sell | S | 557.59 | 600 | 334,554 | 67,134 | 67.7 K to 67.1 K (-0.89 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Sell | S | 556.92 | 100 | 55,692 | 67,734 | 67.8 K to 67.7 K (-0.15 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Payment of Exercise | F | 555.77 | 28,217 | 15,682,162 | 67,834 | 96.1 K to 67.8 K (-29.38 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Buy | M | 52.03 | 52,500 | 2,731,575 | 96,051 | 43.6 K to 96.1 K (+120.55 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Payment of Exercise | F | 555.77 | 17,779 | 9,881,035 | 43,551 | 61.3 K to 43.6 K (-28.99 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Buy | M | 52.03 | 33,079 | 1,721,100 | 61,330 | 28.3 K to 61.3 K (+117.09 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | M | 177.82 | 15,000 | 2,667,300 | 0 | |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 566.01 | 100 | 56,601 | 1,830 | 1.9 K to 1.8 K (-5.18 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 565.35 | 900 | 508,815 | 1,930 | 2.8 K to 1.9 K (-31.80 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 564.45 | 6,600 | 3,725,370 | 2,830 | 9.4 K to 2.8 K (-69.99 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 563.45 | 6,375 | 3,591,994 | 9,430 | 15.8 K to 9.4 K (-40.34 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 562.65 | 1,025 | 576,716 | 15,805 | 16.8 K to 15.8 K (-6.09 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Buy | M | 177.82 | 15,000 | 2,667,300 | 16,830 | 1.8 K to 16.8 K (+819.67 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 5,118 | 2,005,847 | 10,235 | |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 569.20 | 13 | 7,400 | 643 | 656 to 643 (-1.98 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 568.37 | 609 | 346,137 | 656 | 1.3 K to 656 (-48.14 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 567.58 | 646 | 366,657 | 1,265 | 1.9 K to 1.3 K (-33.80 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 566.37 | 2,128 | 1,205,235 | 1,911 | 4 K to 1.9 K (-52.69 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 565.64 | 1,722 | 974,032 | 4,039 | 5.8 K to 4 K (-29.89 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 5,118 | 2,005,847 | 5,761 | 643 to 5.8 K (+795.96 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 520.01 | 9,212 | 4,790,332 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 413.33 | 10,838 | 4,479,671 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 380.95 | 4,960 | 1,889,512 | 2,479 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 376.69 | 7,830 | 2,949,483 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 371.40 | 3,784 | 1,405,378 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 273.67 | 8,500 | 2,326,195 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | M | 177.82 | 5,000 | 889,100 | 0 | |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 556.31 | 4,731 | 2,631,903 | 28,843 | 33.6 K to 28.8 K (-14.09 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 555.25 | 1,595 | 885,624 | 33,574 | 35.2 K to 33.6 K (-4.54 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 554.33 | 2,172 | 1,204,005 | 35,169 | 37.3 K to 35.2 K (-5.82 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 553.16 | 5,423 | 2,999,787 | 37,341 | 42.8 K to 37.3 K (-12.68 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 552.33 | 6,477 | 3,577,441 | 42,764 | 49.2 K to 42.8 K (-13.15 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 551.66 | 7,341 | 4,049,736 | 49,241 | 56.6 K to 49.2 K (-12.97 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 550.58 | 7,295 | 4,016,481 | 56,582 | 63.9 K to 56.6 K (-11.42 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 549.35 | 4,113 | 2,259,477 | 63,877 | 68 K to 63.9 K (-6.05 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 548.17 | 2,597 | 1,423,597 | 67,990 | 70.6 K to 68 K (-3.68 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 547.37 | 1,597 | 874,150 | 70,587 | 72.2 K to 70.6 K (-2.21 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 546.31 | 1,631 | 891,032 | 72,184 | 73.8 K to 72.2 K (-2.21 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 545.34 | 1,390 | 758,023 | 73,815 | 75.2 K to 73.8 K (-1.85 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 544.57 | 405 | 220,551 | 75,205 | 75.6 K to 75.2 K (-0.54 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 543.12 | 1,260 | 684,331 | 75,610 | 76.9 K to 75.6 K (-1.64 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 542.66 | 496 | 269,159 | 76,870 | 77.4 K to 76.9 K (-0.64 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 541.66 | 1,600 | 866,656 | 77,366 | 79 K to 77.4 K (-2.03 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 556.62 | 1 | 557 | 78,966 | 79 K to 79 K (0.00 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 177.82 | 5,000 | 889,100 | 78,967 | 74 K to 79 K (+6.76 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 273.67 | 8,500 | 2,326,195 | 73,967 | 65.5 K to 74 K (+12.98 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 413.33 | 10,838 | 4,479,671 | 65,467 | 54.6 K to 65.5 K (+19.84 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 520.01 | 9,212 | 4,790,332 | 54,629 | 45.4 K to 54.6 K (+20.28 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 376.69 | 7,830 | 2,949,483 | 45,417 | 37.6 K to 45.4 K (+20.83 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 380.95 | 4,960 | 1,889,512 | 37,587 | 32.6 K to 37.6 K (+15.20 %) |
May 07 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Buy | M | 371.40 | 3,784 | 1,405,378 | 32,627 | 28.8 K to 32.6 K (+13.12 %) |
May 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 560.00 | 2,000 | 1,120,000 | 7,643 | 9.6 K to 7.6 K (-20.74 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 528.78 | 1 | 529 | 28,843 | 28.8 K to 28.8 K (0.00 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 527.44 | 1 | 527 | 28,844 | 28.8 K to 28.8 K (0.00 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 524.39 | 6 | 3,146 | 28,845 | 28.9 K to 28.8 K (-0.02 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 523.36 | 1 | 523 | 28,851 | 28.9 K to 28.9 K (0.00 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 522.61 | 7 | 3,658 | 28,852 | 28.9 K to 28.9 K (-0.02 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 521.36 | 17 | 8,863 | 28,859 | 28.9 K to 28.9 K (-0.06 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 520.46 | 22 | 11,450 | 28,876 | 28.9 K to 28.9 K (-0.08 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 519.54 | 18 | 9,352 | 28,898 | 28.9 K to 28.9 K (-0.06 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 518.57 | 15 | 7,779 | 28,916 | 28.9 K to 28.9 K (-0.05 %) |
May 04 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 517.41 | 12 | 6,209 | 28,931 | 28.9 K to 28.9 K (-0.04 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 572.94 | 61 | 34,949 | 15,015 | 15.1 K to 15 K (-0.40 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 571.65 | 112 | 64,025 | 15,076 | 15.2 K to 15.1 K (-0.74 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 570.27 | 125 | 71,284 | 15,188 | 15.3 K to 15.2 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 569.41 | 234 | 133,242 | 15,313 | 15.5 K to 15.3 K (-1.51 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 567.30 | 669 | 379,524 | 15,547 | 16.2 K to 15.5 K (-4.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 566.44 | 1,189 | 673,497 | 16,216 | 17.4 K to 16.2 K (-6.83 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.60 | 1,468 | 830,301 | 17,405 | 18.9 K to 17.4 K (-7.78 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.74 | 377 | 212,907 | 18,873 | 19.3 K to 18.9 K (-1.96 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.58 | 416 | 234,449 | 19,250 | 19.7 K to 19.3 K (-2.12 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.71 | 21 | 11,817 | 19,666 | 19.7 K to 19.7 K (-0.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.57 | 51 | 28,640 | 19,687 | 19.7 K to 19.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 2,720 | 1,511,830 | 19,738 | 22.5 K to 19.7 K (-12.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 22,458 | 17.5 K to 22.5 K (+28.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 3,602 | 2,002,064 | 17,458 | 21.1 K to 17.5 K (-17.10 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 6,622 | 392,022 | 21,060 | 14.4 K to 21.1 K (+45.87 %) |